Skip to main content
Delfa

← Trials/Trial dossier/NCT03840837

CompletedPhase 4

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease

Asset

Rivastigmine

Listed sites

1

Recruiting sites

-

Enrollment

31

actual

Study population

Lewy body dementia

Key I/E criterion

•MoCA 10-25

Primary endpoints

•Timed-Up-and-Go (TUG) duration [s]•NeuroTrax Executive Function score

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Nih3P30AG028747-13S3
Org study IDHP-00084074
NCT IDNCT03840837

Timeline

Milestones

Study first posted2019-02-15actual
Study start2019-05-02actual
Primary completion2020-04-01actual
Study completion2020-04-01actual
Last update posted2023-12-20actual

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

Lewy body dementia

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Age ≥ 18 years.
•Diagnosis of idiopathic Parkinson disease.
•Mild to moderate cognitive impairment, as determined by a MoCA score of ≤ 25 and ≥ 10.
•Patient passes the Evaluation to Sign Consent (ESC) or a legally authorized representative (LAR) is present at the time of enrollment and signs the informed consent form on behalf of the patient.
•Patient is enrolled (or willing to be enrolled) in the University of Maryland Parkinson Disease and Movement Disorders Center PD Research Database (HP 42195)

Exclusion criteria

•Advanced Parkinson disease (Hoehn \& Yahr stage 5), with inability to walk unassisted.
•Other medical condition(s) that significantly interfere(s) with gait and balance (e.g., advanced arthritis).

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Executive function / language
1
Other (unclassified)
1

Executive function / language

1 endpoint
Primary/protocol endpoint

NeuroTrax Executive Function score

Time frame:Data analysis will be completed within 6 months of completing study enrollment.

descriptive

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Timed-Up-and-Go (TUG) duration [s]

Time frame:Data analysis will be completed within 6 months of completing study enrollment.

ratio, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.